Exenteration as palliation for patients with advanced pelvic malignancy.
OBJECTIVE
To examine the place of pelvic exenteration in the palliation of advanced and recurrent pelvic tumours.


METHODS
The notes of patients referred for palliative exenteration were reviewed retrospectively. Fourteen patients (three men, mean age 52 years, and 11 women, mean age 61 years) with a variety of pelvic tumours associated with severe symptoms, had a laparotomy with a view to pelvic exenteration and 10 underwent total or anterior exenteration.


RESULTS
Eight patients achieved excellent or good palliation based on survival and quality of life assessment, and two received no benefit. Four of eight patients were alive and apparently free of tumour at a mean of 17 months after surgery. Four were alive, symptom-free but with evidence of malignancy at a mean of 19 months. Two patients who received no benefit died at 2 and 7 months after surgery. The planned exenteration was abandoned in four patients; three of these four patients were dead at a mean of 13 months and one was alive at 12 months.


CONCLUSIONS
Our results confirm that with careful selection and appropriate multi-specialty care, aggressive pelvic surgery is of value in the palliation of some tumours.
Woodhouse
C R
CR
Department of Urology, Royal Marsden Hospital, London, UK.
Plail
R O
RO
Schlesinger
P E
PE
Shepherd
J E
JE
Hendry
W F
WF
Breach
N M
NM
D000230:Adenocarcinoma / Q000601:surgery*; D002277:Carcinoma / Q000601:surgery*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010166:Palliative Care / Q000379:methods*; D010385:Pelvic Exenteration / Q000009:adverse effects / Q000379:methods; D010386:Pelvic Neoplasms / Q000601:surgery*; D012008:Recurrence; D012189:Retrospective Studies; D016896:Treatment Outcome